Fosaprepitant injection is used along with other medications to prevent nausea and vomiting in adults that may occur within 24 hours or several days after receiving certain cancer chemotherapy treatments.
Fosaprepitant for Injection is a medication used to prevent nausea and vomiting caused by certain anti-cancer (chemotherapy) medicines. It is typically administered in combination with other antiemetic agents. Here are some important details about Fosaprepitant:
Description: Fosaprepitant is a substance P/neurokinin-1 (NK1) receptor antagonist. It is available as a lyophilized powder in single-dose vials for reconstitution. Each vial contains 150 mg of fosaprepitant1.
Indications and Usage:
Fosaprepitant is indicated for the prevention of:
Acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC), including high-dose cisplatin.
Delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC)1.
Limitations of Use: Fosaprepitant has not been studied for the treatment of established nausea and vomiting; it is used for prevention purposes only1.
Dosage and Administration:
Administer fosaprepitant as an intravenous infusion approximately 30 minutes before chemotherapy.
For adults, the recommended dosage on Day 1 is 150 mg administered as an intravenous infusion over 20 to 30 minutes. Concomitant antiemetic medications should also be administered as per the full prescribing information1.
Contraindications:
Known hypersensitivity to any component of this drug.
Concurrent use with pimozide1.
Warnings and Precautions:
CYP3A4 Interactions: Fosaprepitant is a weak inhibitor of CYP3A4, and its active moiety, aprepitant, is a substrate, inhibitor, and inducer of CYP3A4. Caution is advised regarding drug interactions and dosage adjustments when using fosaprepitant with other medications metabolized by CYP3A41.
Hypersensitivity Reactions: Infusion-related hypersensitivity reactions, including anaphylaxis, may occur. Discontinue the drug if symptoms occur during or after infusion1.
Infusion Site Reactions: Be aware of potential infusion site reactions, including thrombophlebitis, necrosis, and vasculitis1.
Remember to consult your healthcare provider for personalized advice regarding the use of Fosaprepitant for Injection in your specific situation. 😊